Phenotypes Associated with This Genotype

Genotype
MGI:5465445

• Allelic Composition: Actl6a^tm1.1Grc/Actl6a^tm1.1Grc; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:192124 )

• progressive after pIpC treatment

hematopoietic system

abnormal definitive hematopoiesis ( J:192124 )

• pIpC-treated mice exhibit bone marrow failure that is hemopoeitic-specific and cell-autonomous

decreased common myeloid progenitor cell number ( J:192124 )

• in the bone marrow of pIpC-treated mice

anemia ( J:192124 )

• aplastic anemia in pIpC-treated mice

decreased bone marrow cell number ( J:192124 )

• progressive after pIpC treatment

decreased megakaryocyte cell number ( J:192124 )

• in the bone marrow of pIpC-treated mice

decreased erythroid progenitor cell number ( J:192124 )

• in the bone marrow and spleen of pIpC-treated mice

increased erythroblast number ( J:192124 )

• in the bone marrow of pIpC-treated mice

decreased erythrocyte cell number ( J:192124 )

• in pIpC-treated mice

polycythemia ( J:192124 )

• in the bone marrow of pIpC-treated mice at the time of death

decreased hemoglobin content ( J:192124 )

• in pIpC-treated mice

thrombocytopenia ( J:192124 )

• in pIpC-treated mice

decreased leukocyte cell number ( J:192124 )

• in pIpC-treated mice

decreased granulocyte number ( J:192124 )

• in the blood and bone marrow of pIpC-treated mice

decreased lymphocyte cell number ( J:192124 )

• in pIpC-treated mice

decreased B cell number ( J:192124 )

• B cell and B-type progenitors in the bone marrow of pIpC-treated mice

decreased macrophage cell number ( J:192124 )

• in the bone marrow and spleen of pIpC-treated mice

decreased monocyte cell number ( J:192124 )

• in pIpC-treated mice

decreased hematopoietic stem cell number ( J:192124 )

• virtual absence of short and long term hematopoietic stem cells (HSCs) in the bone marrow of pIpC-treated mice

• progressive 11-fold decrease as early as 12 days after pIpC treatment

• decreased LT-HSCs in the spleens of pIpC-treated mice

abnormal bone marrow cell physiology ( J:192124 )

• reduced proliferation of long term HSCs, myeloid progenitors, and total bone marrow cells in pIpC-treated mice

• increased apoptosis of myeloid progenitors in pIpC-treated mice

abnormal hematopoietic stem cell physiology ( J:192124 )

• 9-fold decrease in hematopoietic stem cell mobilization to the spleen in pIpC-treated mice

decreased hematopoietic stem cell proliferation ( J:192124 )

• in long term HSCs of pIpC-treated mice

immune system

decreased leukocyte cell number ( J:192124 )

• in pIpC-treated mice

decreased granulocyte number ( J:192124 )

• in the blood and bone marrow of pIpC-treated mice

decreased lymphocyte cell number ( J:192124 )

• in pIpC-treated mice

decreased B cell number ( J:192124 )

• B cell and B-type progenitors in the bone marrow of pIpC-treated mice

decreased macrophage cell number ( J:192124 )

• in the bone marrow and spleen of pIpC-treated mice

decreased monocyte cell number ( J:192124 )

• in pIpC-treated mice

cellular

decreased hematopoietic stem cell proliferation ( J:192124 )

• in long term HSCs of pIpC-treated mice